Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is mycophenolate mofetil really necessary in renal transplantation? A review of the MYSS follow-up study

Nature Clinical Practice Nephrology volume 3, pages 602–603 (2007)Cite this article

boxed-textRemuzzi G et al. (2007) Mycophenolate mofetil versus azathioprine for prevention of chronic allograft dysfunction in renal transplantation: the MYSS follow-up randomized, controlled clinical trial. J Am Soc Nephrol 18: 1973–1985

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Halloran P et al. (1997) Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups. Transplantation 63: 39–47

    Article  CAS  Google Scholar 

  2. Ojo AO et al. (2000) Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. Transplantation 69: 2405–2409

    Article  CAS  Google Scholar 

  3. Meier-Kriesche HU et al. (2003) Mycophenolate mofetil versus azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. Transplantation 75: 1341–1346

    Article  CAS  Google Scholar 

  4. Remuzzi G et al. (2004) Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet 364: 503–512

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Chloë Harman, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. DC Brennan is Professor of Internal Medicine, Director of Transplant Nephrology and Medical Director of Pancreas Transplantation, and MJ Koch is Assistant Professor of Internal Medicine and Medical Director of the High Risk Kidney Transplantation Program, at Washington University School of Medicine, Barnes-Jewish Hospital, St Louis, MO, USA.,

    Daniel C Brennan & Matthew J Koch

Authors
  1. Daniel C Brennan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Matthew J Koch
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Daniel C Brennan.

Ethics declarations

Competing interests

DC Brennan has received grant/research support from Astellas, Genzyme, Novartis, Pfizer and Wyeth; has received speaking honoraria from Genzyme; and has acted as a consultant for Genzyme, Pfizer and Wyeth. MJ Koch has received grant/research support from Genzyme and speaking honoraria from Astellas.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Brennan, D., Koch, M. Is mycophenolate mofetil really necessary in renal transplantation? A review of the MYSS follow-up study. Nat Rev Nephrol 3, 602–603 (2007). https://doi.org/10.1038/ncpneph0597

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpneph0597

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing